← Back to patent-cliff list
CAS 74-83-9
Bromomethane
Codes: Clarithromycin-026
Application context (from source-drug indications)
Marginal zone B-cell lymphomaClarithromycin/Rabeprazole Sodium/AmoxicillinDuodenal ulcerClarithromycin/Rabeprazole Sodium/AmoxicillinImmune thrombocytopenic purpuraClarithromycin/Rabeprazole Sodium/AmoxicillinGastric ulcerClarithromycin/Rabeprazole Sodium/AmoxicillinGastritisClarithromycin/Rabeprazole Sodium/AmoxicillinHelicobacter pylori infectionClarithromycin/Rabeprazole Sodium/AmoxicillinSinusitisClarithromycinTonsillitisClarithromycinAcute bronchitisClarithromycinChronic bronchitisClarithromycinLower respiratory tract infectionClarithromycinPharyngitisClarithromycin
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Clarithromycin/Rabeprazole Sodium/Amoxicillin | Tier C — Watch / trade | - |
| Clarithromycin | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Clarithromycin/Rabeprazole Sodium/AmoxicillinOptimised routesteps: 5total yield: 17.5g(Clarithromycin (Free))
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-7,12,13-trihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione thiocyanate→Thiocyanic acid--(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy]-14-ethyl-7,12,13-trihydroxy-10-(hydroxyimino)-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one (1/1)→(3R,4S,5S,6R,7R,9R,10Z,11S,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-7,12,13-trihydroxy-10-(hydroxyimino)-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one→2-Ethoxyprop-1-ene→(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy]-10-[[(2-ethoxypropan-2-yl)oxy]imino]-14-ethyl-7,12,13-trihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one→(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(Dimethylamino)-6-methyl-3-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-10-[[(2-ethoxypropan-2-yl)oxy]imino]-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one→Methyl iodide→Bromomethane→(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(Dimethylamino)-6-methyl-3-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-10-[[(2-ethoxypropan-2-yl)oxy]imino]-14-ethyl-12,13-dihydroxy-7-methoxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-7,12,13-trihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione thiocyanate→Thiocyanic acid--(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy]-14-ethyl-7,12,13-trihydroxy-10-(hydroxyimino)-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one (1/1)→(3R,4S,5S,6R,7R,9R,10Z,11S,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-7,12,13-trihydroxy-10-(hydroxyimino)-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one→2-Ethoxyprop-1-ene→(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy]-10-[[(2-ethoxypropan-2-yl)oxy]imino]-14-ethyl-7,12,13-trihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecan-2-one→(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(Dimethylamino)-6-methyl-3-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-10-[[(2-ethoxypropan-2-yl)oxy]imino]-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one→Methyl iodide→Bromomethane→(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(Dimethylamino)-6-methyl-3-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-10-[[(2-ethoxypropan-2-yl)oxy]imino]-14-ethyl-12,13-dihydroxy-7-methoxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)oxy]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.